403 Phase I study on RGB-286638, a novel, multi-targeted protein kinase inhibitor, administered as a 1-hour infusion on five consecutive days every 4 weeks in patients (pts) with recurrent or refractory solid tumors

✍ Scribed by M. de Jonge; R. Mathijssen; W. Loos; H. Loferer; S. Sperka; T. Meyer; E. Wiemer; D. van der Biessen; H. Burger; J. Verweij

• Book ID: 119603086
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 48 KB
• Volume: 8
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(10)72110-8